Saving of up to $1600 ends
- 00Days
- 00Hrs
- 00Mins
- 00Secs
RNA Leaders USA 2024 Highlights
A huge thank you to everyone who joined us for the 3rd edition of the RNA Leaders USA Congress, and for the first time on the West Coast!
We were thrilled to have fantastic support from the investor community, who connected with some of the most senior decision-makers from RNA biotech companies and large pharma. Attendees also benefited from insights shared by industry experts representing a diverse range of organizations, including academia and innovative biotech institutes.
The partneringONE meeting platform facilitated numerous formal 1-to-1 meetings, complementing the hours of informal networking opportunities.
We’re already gearing up for 2025! Join us as we return to the West Coast in Boston from September 10 - 11, 2025.
+
Registered Attendees
+
Meeting Requests
+
Licensing Opportunities
2024 Delegate Breakdown
Countries Represented
North American Region Represented
Industries Represented
Attendee Seniority
2024 Attendee List
RNA Leaders USA Congress attracts decision-makers from biotech, big pharma, investors, academia and the services needed to help bring products to market faster.
Real Voices from RNA Leaders USA 2024...
I had a terrific time catching up with the newest and greatest in the RNA therapeutics space, but more importantly, getting reacquainted with colleagues and friends in the industry. I highly recommend the event to both industry and academic leaders and trainees.
Eugene Yeo, Professor,
University Of California
San Diego
RNA Leaders congresses bring together technology and drug developers, pharma companies and investors. Excellent topics and panels, and sufficient time for meeting prospective partners and investors. I recommend it to those in the genetic medicines field.
David Slack, Chief Executive Officer,
Impilo Therapeutics
RNA leaders USA brings together the main players in the field. The meeting highlights new developments in all areas of therapeutic RNAs from fundamental chemistry to clinical applications which are essential for the selection of future RNA-based therapies.
Gilles Divita, CEO
Divincell
